BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5:243-250. [PMID: 18332995 DOI: 10.1080/13651820310015833] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Di Bisceglie AM, Strasberg S. A common staging system for hepatocellular carcinoma. Hepatology 2004;39:550-1. [DOI: 10.1002/hep.20072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
2 Chang L, Wang Y, Zhang J, Guo T. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget 2017;8:20418-27. [PMID: 28099898 DOI: 10.18632/oncotarget.14668] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
3 Hsieh SY, Huang SF, Yu MC, Yeh TS, Chen TC, Lin YJ, Chang CJ, Sung CM, Lee YL, Hsu CY. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010;49:476-87. [PMID: 20232364 DOI: 10.1002/mc.20627] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
4 Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, Rutman AM, Siripongsakun S, Lu D, Imanbayev G, Kuo MD. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 2015;62:792-800. [PMID: 25930992 DOI: 10.1002/hep.27877] [Cited by in Crossref: 145] [Cited by in F6Publishing: 145] [Article Influence: 24.2] [Reference Citation Analysis]
5 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
6 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989-994. [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
7 Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922. [PMID: 17522517 DOI: 10.1097/01.sla.0000254368.65878.da] [Cited by in Crossref: 220] [Cited by in F6Publishing: 217] [Article Influence: 15.7] [Reference Citation Analysis]
8 Zhu LZ, Xu S, Qian HL. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. World J Gastroenterol 2018; 24(23): 2501-2507 [PMID: 29930471 DOI: 10.3748/wjg.v24.i23.2501] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 443] [Cited by in F6Publishing: 405] [Article Influence: 27.7] [Reference Citation Analysis]
10 Ogihara H, Iizuka N, Hamamoto Y. Prediction of Early Recurrence of Liver Cancer by a Novel Discrete Bayes Decision Rule for Personalized Medicine. Biomed Res Int 2016;2016:8567479. [PMID: 27800494 DOI: 10.1155/2016/8567479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Gong XY, Ma N, Xu HX, Chen F, Huang XH, Wang Q. Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery. Oncol Lett 2018;15:3796-805. [PMID: 29467897 DOI: 10.3892/ol.2018.7733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Kim IG, Hu XG, Wang HJ, Kim BW, Hong SY, Shen XY. The 7th/8th American Joint Committee on Cancer and the Modified Union for International Cancer Control Staging System for Hepatocellular Carcinoma. Yonsei Med J 2019;60:140-7. [PMID: 30666835 DOI: 10.3349/ymj.2019.60.2.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Delis SG, Bakoyiannis A, Dervenis C, Tassopoulos N. Perioperative risk assessment for hepatocellular carcinoma by using the MELD score. J Gastrointest Surg 2009;13:2268-75. [PMID: 19662460 DOI: 10.1007/s11605-009-0977-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
14 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 13.3] [Reference Citation Analysis]
15 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 329] [Article Influence: 48.4] [Reference Citation Analysis]
16 Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005;25 Suppl 1:S3-23. [PMID: 16227495 DOI: 10.1148/rg.25si055507] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
17 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
18 Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatology Research 2007;37:S206-9. [DOI: 10.1111/j.1872-034x.2007.00186.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
19 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056-1066. [PMID: 24613269 DOI: 10.1016/j.jvir.2014.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
21 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-115; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gas20637944,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Grosfeld JL, Otte J. Liver Tumors in Children. In: Carachi R, Grosfeld JL, Azmy AF, editors. The Surgery of Childhood Tumors. Berlin: Springer Berlin Heidelberg; 2008. pp. 227-60. [DOI: 10.1007/978-3-540-29734-5_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-1215; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gassur.2005.09.008] [Cited by in Crossref: 170] [Cited by in F6Publishing: 140] [Article Influence: 11.3] [Reference Citation Analysis]
24 Colombo M, Sangiovanni A. The strategic role of staging in the treatment of HCC. Hepatology 2004;39:552-3. [DOI: 10.1002/hep.20112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
25 Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:485-9. [DOI: 10.1097/00042737-200505000-00003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
26 Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, Martinie JB, Russo MW, Iannitti DA. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014;16:1102-9. [PMID: 24964271 DOI: 10.1111/hpb.12300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
27 Hsu C, Shen Y, Cheng C, Hu F, Cheng A. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials 2010;31:55-61. [DOI: 10.1016/j.cct.2009.08.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
28 Zhang T, Liu Z, Zhao X, Mao Z, Bai L. A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients. Artif Cells Nanomed Biotechnol 2019;47:2246-55. [PMID: 31169437 DOI: 10.1080/21691401.2019.1573174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
29 Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, Kim WT, Byun JH. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352-361. [PMID: 18008352 DOI: 10.1002/cncr.23185] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 6.4] [Reference Citation Analysis]
30 Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, Sakamoto K, Ueno T, Hazama S, Ogihara H. An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 2015;46:944-952. [PMID: 25524574 DOI: 10.3892/ijo.2014.2798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
31 Attallah AM, Omran MM, Attallah AA, Abdelrazek MA, Farid K, El-dosoky I. Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. Int J Clin Oncol 2017;22:332-9. [DOI: 10.1007/s10147-016-1066-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
32 Addario L, Tritto G, Cavaglià E, Amodio F, Giannelli E, Di Costanzo GG. Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Dig Liver Dis. 2011;43:319-324. [PMID: 20952262 DOI: 10.1016/j.dld.2010.09.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
33 Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, Brouquet A, Adams RB; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:289-299. [PMID: 20590901 DOI: 10.1111/j.1477-2574.2010.00181.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 11.1] [Reference Citation Analysis]
34 Zhao L, Mou DC, Peng JR, Huang L, Wu ZA, Leng XS. Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients. World J Gastroenterol 2010; 16(32): 4072-4078 [PMID: 20731022 DOI: 10.3748/wjg.v16.i32.4072] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pascual S, Zapater P, Such J, Garcia-herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006;26:673-9. [DOI: 10.1111/j.1478-3231.2006.01282.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
36 Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, Yano M, Ishikawa O, Imaoka S. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244:771-780. [PMID: 17060771 DOI: 10.1097/01.sla.0000225126.56483.b3] [Cited by in Crossref: 111] [Cited by in F6Publishing: 105] [Article Influence: 7.4] [Reference Citation Analysis]
37 Burns JM, Greene FL. Controversies in staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2005;12:456-62. [DOI: 10.1007/s00534-005-1030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
39 Daniele B, Perrone F. Staging for Liver Cancer. Clinics in Liver Disease 2005;9:213-23. [DOI: 10.1016/j.cld.2004.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
40 Vauthey J, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, Lerut J, Chapman WC, Hemming AW, Neuhaus P. Outcomes of Liver Transplantation in 490 Patients with Hepatocellular Carcinoma: Validation of a Uniform Staging after Surgical Treatment. Journal of the American College of Surgeons 2007;204:1016-27. [DOI: 10.1016/j.jamcollsurg.2006.12.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
41 Li K, Wang HT, He YK, Guo T. New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis. Medicine (Baltimore) 2017;96:e6950. [PMID: 28514316 DOI: 10.1097/MD.0000000000006950] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
42 Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH. Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. Front Immunol 2019;10:2093. [PMID: 31552039 DOI: 10.3389/fimmu.2019.02093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
43 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
44 Taniai N, Yoshida H, Tajiri T. Adaptation of hepatectomy for huge hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:410-416. [PMID: 18670843 DOI: 10.1007/s00534-007-1317-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
45 Chan AC, Fan ST, Poon RT, Cheung TT, Chok KS, Chan SC, Lo CM. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford). 2013;15:439-448. [PMID: 23659567 DOI: 10.1111/j.1477-2574.2012.00617.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
46 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
47 She WH, Chan ACY, Ma KW, Dai WC, Chok KSH, Cheung TT, Lo CM. Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma. Ann Transl Med 2021;9:919. [PMID: 34350234 DOI: 10.21037/atm-20-7611] [Reference Citation Analysis]
48 Sirivatanauksorn Y, Tovikkai C. Comparison of staging systems of hepatocellular carcinoma. HPB Surg. 2011;2011:818217. [PMID: 21760664 DOI: 10.1155/2011/818217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
49 Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, Fujita Y, Hamamoto Y, Iizuka N, Ueno T, Nagano H. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett 2018;15:4411-22. [PMID: 29556288 DOI: 10.3892/ol.2018.7821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
50 Albadawi H, Zhang Z, Altun I, Hu J, Jamal L, Ibsen KN, Tanner EEL, Mitragotri S, Oklu R. Percutaneous liquid ablation agent for tumor treatment and drug delivery. Sci Transl Med 2021;13:eabe3889. [PMID: 33568519 DOI: 10.1126/scitranslmed.abe3889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405. [PMID: 15565571 DOI: 10.1002/hep.20486] [Cited by in Crossref: 243] [Cited by in F6Publishing: 234] [Article Influence: 14.3] [Reference Citation Analysis]
52 Ruiz E, Rojas Rojas T, Berrospi F, Chávez I, Luque C, Cano L, Doimi F, Pineau P, Deharo E, Bertani S. Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. Heliyon 2016;2:e00052. [PMID: 27441236 DOI: 10.1016/j.heliyon.2015.e00052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
53 Huang W, Jeng Y, Lai H, Sheu FB, Lai P, Yuan R. Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma. Langenbecks Arch Surg 2015;400:725-34. [DOI: 10.1007/s00423-015-1329-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
54 Contreras CM, Vauthey JN. Staging systems: Is there a surgical staging and a medical one? A surgeon's perspective. J Hepatobiliary Pancreat Sci 2010;17:438-9. [PMID: 19882373 DOI: 10.1007/s00534-009-0243-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52. [PMID: 23374755 DOI: 10.1186/1471-2407-13-52] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
56 Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, Seong J, Lee IJ, Jang HS, Kay CS. Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat. 2014;46:348-357. [PMID: 25036573 DOI: 10.4143/crt.2013.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
57 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 13.9] [Reference Citation Analysis]
58 Delis SG, Bakoyiannis A, Dervenis C, Tassopoulos N. Perioperative risk assessment for hepatocellular carcinoma by using the MELD score. J Gastrointest Surg. 2009;13:2268-2275. [PMID: 19662460 DOI: 10.1007/s11605-009-0977-5.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Cha C. Surgical Therapy for Hepatocellular Carcinoma: Formulating a Rational Approach. Journal of Clinical Gastroenterology 2013;47:S30-6. [DOI: 10.1097/mcg.0b013e31829440bd] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Zangan SM, Patel J. Chemoembolization for Hepatocellular Carcinoma. Seminars in Roentgenology 2011;46:105-14. [DOI: 10.1053/j.ro.2010.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Endo M, Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol 2016;4:515-22. [PMID: 27073653 DOI: 10.3892/mco.2016.755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
62 Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakajima M, Suzuki N, Takeda S, Wada H, Kobayashi S, Eguchi H, Ueno T, Nagano H. Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. Oncol Lett 2019;18:3903-13. [PMID: 31516601 DOI: 10.3892/ol.2019.10688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568-2575. [PMID: 21835608 DOI: 10.1016/j.ejca.2011.07.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
64 Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127:S194-S205. [PMID: 15508085 DOI: 10.1053/j.gastro.2004.09.034] [Cited by in Crossref: 241] [Cited by in F6Publishing: 210] [Article Influence: 14.2] [Reference Citation Analysis]
65 Vauthey JN, Lauwers GY. Surgically resected hepatocellular carcinoma: protean yet predictable. Ann Surg Oncol 2005;12:270-2. [PMID: 15827674 DOI: 10.1245/ASO.2005.12.916] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Vauthey JN, Pawlik TM, Lauwers GY, Nagorney DM, Roh MS, Curley SA, Poon RT, Belghiti J, Greene F, Michael Henderson J. Critical evaluation of the different staging systems for hepatocellular carcinoma (Br J Surg 2004; 91: 400-408). Br J Surg 2004;91:1072. [PMID: 15286973 DOI: 10.1002/bjs.4782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
67 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 26.0] [Reference Citation Analysis]
68 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatology Research 2007;37:S210-5. [DOI: 10.1111/j.1872-034x.2007.00187.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
69 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
70 Huang J, Zhang Y, Peng Z, Gao H, Xu L, Jiao LR, Chen M. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol. 2013;139:1709-1719. [PMID: 23982274 DOI: 10.1007/s00432-013-1497-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
71 Cheung TT, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC, Fan ST, Lo CM. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg. 2013;257:506-511. [PMID: 23299521 DOI: 10.1097/sla.0b013e31827b947a] [Cited by in Crossref: 150] [Cited by in F6Publishing: 84] [Article Influence: 18.8] [Reference Citation Analysis]
72 Alswat KA, Sanai FM, Altuwaijri M, Albenmousa A, Almadi M, Al-Hamoudi WK, Abdo AA. Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population. Hepat Mon 2013;13:e7612. [PMID: 23922558 DOI: 10.5812/hepatmon.7612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
73 Nathan H, Mentha G, Marques HP, Capussotti L, Majno P, Aldrighetti L, Pulitano C, Rubbia-Brandt L, Russolillo N, Philosophe B, Barroso E, Ferrero A, Schulick RD, Choti MA, Pawlik TM. Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford) 2009;11:382-90. [PMID: 19768142 DOI: 10.1111/j.1477-2574.2009.00070.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
74 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
75 Pant V, Sen IB, Soin AS. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun 2013;34:749-57. [PMID: 23689586 DOI: 10.1097/MNM.0b013e3283622eef] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
76 Li B, Yuan Y, Chen G, He L, Zhang Y, Li J, Li G, Lau WY. Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer 2010;10:535. [PMID: 20925965 DOI: 10.1186/1471-2407-10-535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
77 Colombo M. Natural history of hepatocellular carcinoma. Cancer Imaging 2005;5:85-8. [PMID: 16154825 DOI: 10.1102/1470-7330.2005.0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
78 Bruix J, Llovet JM. Prognostic prediction in HCC: Did anybody expect it to be easy? Hepatology 2004;39:551-2. [DOI: 10.1002/hep.20050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
79 Tanriverdi O. A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist's perspective. Med Oncol. 2014;31:282. [PMID: 25316265 DOI: 10.1007/s12032-014-0282-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
80 Young RS, Aldiwani M, Hakeem AR, Nair A, Guthrie A, Wyatt J, Treanor D, Morris-Stiff G, Jones RL, Prasad KR. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford). 2013;15:418-427. [PMID: 23458127 DOI: 10.1111/hpb.12008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
81 Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: An attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011650. [PMID: 28351116 DOI: 10.1002/14651858.cd011650.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
82 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol 2013; 19(11): 1811-1819 [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 68] [Article Influence: 8.4] [Reference Citation Analysis]